http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113292548-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02 |
| filingDate | 2021-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113292548-B |
| titleOfInvention | Preparation of quercetin-conjugated hydrogen sulfide donor and application of quercetin-conjugated hydrogen sulfide donor in treatment of diabetes and wound healing |
| abstract | The invention belongs to the technical field of preparation of medicines for treating diabetes and wound healing thereof, and particularly relates to quercetin-3-O-acetic acid- (4- (3H-1, 2-dithiole-3-thioketone)) -phenyl ester and application thereof in preparation of medicines for treating diabetes and wound healing thereof. The invention uses rutin as raw material, through twice substitution hydrolysis reactions, reduces to generate quercetin-3-O-acetic acid, makes it and hydrogen sulfide donor 5- (4-hydroxy phenyl) -3H-1, 2-dithiole-3-thioketone successfully prepare compound entity capable of treating diabetes and promoting wound healing through condensation reaction. In HUVECs cell experiments, cell proliferation experiments prove that the composition can promote the growth of HUVECs cells, and scratch experiments and in-vitro tubulogenesis experiments further prove that the composition can promote the wound healing of diabetic patients. The drug is verified to have no damage to liver cells in a HepG2 cytotoxicity experiment, and the compound is verified to have the similar hypoglycemic effect with the commercial drug metformin by the treatment of an insulin resistance model. |
| priorityDate | 2021-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 84.